Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization.
The efficacy of novel monoclonal antibodies that neutralize the pro-angiogenic mediator, sphingosine-1-phosphate (S1P), were tested using in vitro and in vivo angiogenesis models, including choroidal neovascularization (CNV) induced by laser disruption of Bruch's membrane. S1P receptor levels in human brain choroid plexus endothelial cells (CPEC), human lung microvascular endothelial cells, human retinal vascular endothelial cells, and circulating endothelial progenitor cells were examined by semi-quantitative PCR. The ability of murine or humanized anti-S1P monoclonal antibodies (mAbs) to inhibit S1P-mediated microvessel tube formation by CPEC on Matrigel was evaluated and capillary density in subcutaneous growth factor-loaded Matrigel plugs was determined following anti-S1P treatment. S1P promoted in vitro capillary tube formation in CPEC consistent with the presence of cognate S1P(1-5) receptor expression by these cells and the S1P antibody induced a dose-dependent reduction in microvessel tube formation. In a murine model of laser-induced rupture of Bruch's membrane, S1P was detected in posterior cups of mice receiving laser injury, but not in uninjured controls. Intravitreous injection of anti-S1P mAbs dramatically inhibited CNV formation and sub-retinal collagen deposition in all treatment groups (p<0.05 compared to controls), thereby identifying S1P as a previously unrecognized mediator of angiogenesis and subretinal fibrosis in this model. These findings suggest that neutralizing S1P with anti-S1P mAbs may be a novel method of treating patients with exudative age-related macular degeneration by reducing angiogenesis and sub-retinal fibrosis, which are responsible for visual acuity loss in this disease.
Caballero
Sergio
S
Department of Pharmacology & Therapeutics, University of Florida, Gainesville, FL, USA.
Swaney
James
J
Moreno
Kelli
K
Afzal
Aqeela
A
Kielczewski
Jennifer
J
Stoller
Glenn
G
Cavalli
Amy
A
Garland
William
W
Hansen
Geneviève
G
Sabbadini
Roger
R
Grant
Maria B
MB
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D003094:Collagen; D004195:Disease Models, Animal; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005260:Female; D005355:Fibrosis / Q000517:prevention & control; D015870:Gene Expression; D007797:Laminin; D007834:Lasers; D008246:Lysophospholipids / Q000032:analysis / Q000276:immunology* / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D018919:Neovascularization, Physiologic / Q000187:drug effects; D011509:Proteoglycans; D012333:RNA, Messenger / Q000235:genetics; D011817:Rabbits; D049349:Receptors, Lysosphingolipid / Q000096:biosynthesis / Q000235:genetics; D012160:Retina / Q000473:pathology; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000032:analysis / Q000276:immunology / Q000494:pharmacology; D014822:Vitreous Body / Q000737:chemistry
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D004338:Drug Combinations; D007797:Laminin; D008246:Lysophospholipids; D011509:Proteoglycans; D012333:RNA, Messenger; D049349:Receptors, Lysosphingolipid; C059485:matrigel; C060506:sphingosine 1-phosphate; D003094:Collagen; D013110:Sphingosine